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ABSTRACT
The intestinal microbiome has been identified as a key modifier for a variety of health conditions. 
Fecal Microbiota Transplantation (FMT) has emerged as a fast, safe, and effective means by which to 
modify the intestinal microbiome and potentially treat a variety of health conditions. Despite 
extensive research of FMT for CDI, there is a lack of clarity informed by systematic synthesis of 
data regarding the safety and efficacy of FMT for other health conditions. This systematic review 
used PRISMA guidelines and was prospectively registered with PROSPERO (CRD42018104243). In 
March 2020, a search of MEDLINE, EMBASE, and PsycINFO was conducted. We identified 26 eligible 
studies. A meta-analysis of FMT for active Ulcerative Colitis (UC) showed that FMT significantly 
improved rates of clinical remission (OR = 3.634, 95% CI = 1.940 to 6.808, I2 = 0%, p < .001), clinical 
response (OR = 2.634, 95% CI = 1.441 to 4.815, I2 = 33%, p = .002) and endoscopic remission 
(OR = 4.431, 95% CI = 1.901 to 10.324, I2 = 0%, p = .001). With respect to Irritable Bowel Syndrome, 
a meta-analysis showed no significant change in symptoms following FMT (p = .739). Hepatic 
disorders, metabolic syndrome, and antibiotic-resistant organisms were conditions with emerging 
data on FMT. Serious adverse events (AE) were more often reported in control group participants 
(n = 43) compared with FMT group participants (n = 26). There were similar rates of mild to 
moderate AE in both groups. Preliminary data suggest that FMT is a potentially safe, well- 
tolerated and efficacious treatment for certain conditions other than CDI, with evidence for active 
UC being the most compelling.
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Introduction
The intestinal microbiome has emerged as 
a modifiable target for treating a variety of health 
conditions thought to be associated with dysregu-
lated microbiome profiles.1 The intestinal micro-
biome is believed to have a key role in modifying 
immunity, inflammation, and – by extension – 
a plethora of health conditions.2–4 There is now 
substantial research interest5 into interventions that 
might target the gut microbiome to improve chronic 
diseases, including diet, supplementary prebiotics, 
probiotics, antibiotics, short-chain fatty acids, and 
Fecal Microbiota Transplantation (FMT).6,7
FMT is a technique in which gut bacteria are 
transferred from a healthy donor to a patient, 
with the goal of introducing or restoring a stable 
microbial community in the gut. FMT has been 
established as an effective means of rapidly modify-
ing the intestinal microbiota and may therefore 
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have potential as a treatment for the many health 
conditions linked with the intestinal microbiome.8 
FMT is already widely practiced as a highly effective 
treatment for recurrent Clostridium difficile infec-
tion (CDI).9,10
A wealth of new research is investigating whether 
FMT may be used to treat other health conditions 
linked to the intestinal microbiome,11,12 including 
gastrointestinal,13–17 autoimmune,18,19 metabolic,20,21 
and neuropsychiatric22–24 conditions. There is also 
promising preclinical evidence supporting the use of 
FMT in conditions other than CDI, including Major 
Depressive Disorder,25,26 schizophrenia,27 and cardi-
ometabolic syndrome.28
While reviews of FMT for specific indications 
such as IBS29–31 and IBD exist,32–34 to date there 
have been no comprehensive reviews evaluating 
and synthesizing the entire body of data for both 
the efficacy and safety of FMT for all conditions 
other than CDI. This systematic review and meta- 
analysis addresses the question of whether FMT is 
safe and effective at treating health conditions other 
than CDI in humans.
Methods
Protocol and registration
The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines 
were adhered to as a methodological template for 
this review. The protocol for this Systematic Review 
was prospectively registered with PROSPERO 
(CRD42018104243).
Search strategy and eligibility criteria
The PICO approach (population, intervention, 
comparator, outcomes) was used to guide the 
search strategy for this review. The PICO criteria 
used are outlined below:
● Population: Humans participants of any age 
with any acute or chronic health condition 
other than CDI. Studies were included only if 
participants were followed up for at least two 
weeks post-FMT.
● Intervention: All possible variations of human 
FMT were included. For the purposes of this 
review, FMT was defined as any process by 
which a fecal microbiota suspension was trans-
ferred from the gastrointestinal tract of 
a healthy individual into another person with 
the aim of treating a health condition.35
● Comparator: Studies were included if they uti-
lized a control group.
● Outcomes: When reporting on efficacy, this review 
used primary outcome measures as described by 
each study. When the primary outcome did not 
relate to efficacy, the secondary outcomes relating 
to clinical efficacy were noted, but results were only 
considered significant when the primary outcome 
measure related to clinical efficacy and was statisti-
cally significant vs the control intervention. Adverse 
events (AE) were reported as presented by the 
included study.
In March 2020, searches were carried out using 
MEDLINE, EMBASE, Cochrane Central Register of 
Controlled Trials, Health Technology Assessment 
Database, Allied and Complementary Medicine 
(AMED) and PsycINFO. Reference sections of pre-
viously published randomized trials, systematic reviews, 
and meta-analyses on this and related topics were also 
searched.
Forty-two iterations of the term “FMT” were 
identified and used as search terms:
FMT or fecal microbiota transplant* or fecal 
microbiota transplant* or microbiota transfer or 
microbiome transfer or microbiota transplant* 
OR microbiome transplant* or microbial trans-
plant* or microbial transfer or fecal transplant* 
OR fecal transplant* or feces transplant* OR 
feces transplant* or stool transplant* or stool 
transfer or fecal flora transplant* OR fecal flora 
transplant* or microflora transplant* OR fecal 
flora transfer or fecal flora transfer OR fecal 
bacteriotherapy OR fecal bacteriotherapy OR 
feces bacteriotherapy OR feces bacteriotherapy 
OR rectal bacteriotherapy OR fecal flora bacter-
iotherapy OR donor fecal OR donor stool OR 
donor feces OR donor fecal or donor feces fecal 
transfer OR fecal transfer OR fecal reconstitu-
tion OR fecal reconstitution OR flora reconstitu-
tion OR microbiome reconstitution OR feces 
reconstitution or feces reconstitution. The fol-
lowing modifiers were applied: studies relating 
to humans and published in English.
e1854640-2 J. E. GREEN ET AL.
Study selection
The following study types were included: rando-
mized controlled trials (RCTs), non-randomized- 
controlled studies, and observational studies with 
a comparator arm. In the case of observational 
studies with a comparator arm, only prospective 
cohort studies were included in order to assess 
temporality. Reviews, abstracts, conference papers, 
and posters were excluded.
Two investigators (JG and JD) independently 
performed the searches using Rayyan software. JG 
performed initial screening to identify potentially 
eligible studies. Articles were first screened by title 
and abstract. Remaining articles were further scru-
tinized by full-text review. JD acted as a secondary 
reviewer and was blind to JG’s screening outcomes. 
Where there was a lack of consensus between the 
two reviewers, the senior author (WM) acted as 
a third reviewer to make a final decision on whether 
the study met inclusion criteria.
Risk of bias assessment
Methodological heterogeneity was evaluated by 
comparing included data using the ‘risk of bias’ 
tables. The Cochrane Risk of Bias tool was used to 
assess the risk of bias in randomized trials. JG and 
JD independently evaluated risk of bias.36
Statistical analysis
Data from individual trials were to be combined, 
and a meta-analysis performed only if the data were 
amenable. Patient groups, disease entity, and out-
come measures needed to be sufficiently similar in 
order for synthesis to occur. Our meta-analyses 
were conducted in Comprehensive Meta-Analysis 
(version 3.3.070)37 using a Mantel-Haenszel ran-
dom-effects model to account for heterogeneity 
between studies. The I2-statistic was used as an 
indicator of heterogeneity. A value of 0% indicates 
no observed heterogeneity, and larger values indi-
cate increasing heterogeneity. Due to the limited 
number of studies included in each meta-analysis, 
no sensitivity or subgroup analyses were per-
formed. Furthermore, no test of publication bias 
was performed due to the limited number of 
trials.38
Assessment of microbial “engraftment”
This review also assessed whether successful 
“engraftment” occurred of the donor microbiome 
in the recipient. For the purposes of this review, the 
term “engraftment” was ascertained according to 
the following key concepts:
● Was a change in recipient microbiota observed 
following FMT?
If a change in recipient microbiota was observed, 
then:
● Was this change toward the donor microbiota?
● To what extent/how significant was that 
change?
● For how long did the microbiota changes per-
sist following cessation of FMT?
Results
Study selection
The systematic search identified 5,495 de-duplicated 
studies, of which 26 met eligibility criteria for inclu-
sion (see Figure 1).
Study characteristics
As per Table 1, of the 26 articles that were included 
in the final review, 20 were Randomized Controlled 
Trials (RCTs), two of which were open-label, three 
single-blind and 15 double-blind. The remaining 
six studies encompassed non-randomized- 
controlled studies (n = 3), case–control studies 
(n = 2), and cohort studies (n = 1). Eight studies 
investigated the use of FMT for Inflammatory 
Bowel Disease (IBD), six for functional gut disor-
ders, four for hepatic disorders, three for metabolic 
syndrome, two for antibiotic-resistant organisms, 
and one each for “pouchitis,” obesity without meta-
bolic syndrome, and Human Immunodeficiency 
Virus (HIV).
A total of 1149 participants were enrolled in the 
included studies, with a mean of 44 participants per 
study (sample sizes ranged from 6 to 165). When 
broken down by disorder, there were a total of 463 
GUT MICROBES e1854640-3
participants in studies relating to IBD, 424 for func-
tional gut disorders, 104 for metabolic syndrome/ 
obesity, 109 for hepatic disorders, 60 for antibiotic- 
resistant organisms, and 14 for other disorders. 
Study follow-up periods varied from 2 weeks to 
12 months. The largest sub-groups by disorder 
were UC (n = 6) and irritable bowel syndrome 
(IBS) (n = 5). These groups were large enough to 
allow for meta-analyses.
Seventeen studies included both males and 
females, eight included males only, and one did 
not provide demographic data. Studies were con-
ducted in US (n = 6),41,44,47–51 The Netherlands 
(n = 4),39,42,43,52 Australia (n = 2),53,54 China 
(n = 2), Norway (n = 2),14,40 France (n = 2),45,46 
India (n = 2), Denmark (n = 1), Japan (n = 1),55 
Austria (n = 1),56 Canada (n = 1),57 Sweden 
(n = 1),58 and one was an international multi-site 
collaborative study between Switzerland, the 
Netherlands, Israel, and France.59
Methodological factors for FMT manufacture 
process
The FMT manufacture process varied significantly 
between studies (see Table 1); indeed, no two studies 
used the same process. Of the 26 included FMT 
studies, 11 delivered FMT via colonoscopy, enema, 
Figure 1. PRISMA flowchart of included studies.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































e1854640-8 J. E. GREEN ET AL.
or both,14,45,47,48,53–58,60 nine were delivered endosco-
pically, either via nasojejunal tube,61nasoduodenal 
tube39,40,42,43,52,62,63 or nasogastric tube;46 four were 
delivered orally via encapsulated FMT;41,49,50,64 and 
two studies used a mixed methodology of endo-
scopic delivery or encapsulated FMT,59 or endo-
scopic route followed by encapsulated FMT.51 
Twenty two studies used an aerobic preparation 
of FMT,14,40,42,43,45–50,52,53,55–63 one used an anae-
robic preparation,54 and two did not specify.41,51 
Two used a semi-anaerobic preparation of FMT 
(33, 37) in which feces was exposed to some oxy-
gen during the procedure but attempts were made 
to minimize this; for example, prior to prepara-
tion, feces was stored in oxygen-depleted saline 
solution (36). Five studies used fresh feces, four 
used frozen feces, and two protocols allowed for 
use of fresh or frozen feces. One protocol did not 
describe whether feces were fresh or frozen.63
Dose
Dosing was inconsistently described. Twelve stu-
dies did not provide clear information regarding 
amount of stool used. Fourteen studies reported on 
the initial sample of fresh stool, whilst eight 
described the amount of “suspension” used, which 
consisted of filtered stool diluted with normal saline 
and sometimes mixed with a cryoprotectant such as 
glycerol. Doses of 12 g-250 g of fresh stool were 
reported in the 14 studies that did provide these 
data.
Adjunctive treatments
A wide range of adjunctive treatments were 
employed. Fourteen studies used bowel 
preparation,14,39,42,43,45,47,52–56,58,60 and six studies 
used antibiotics.44,46,48,55,56,59,62 Ren et al63 did not 
state whether bowel preparation was used and 
Herfarth et al51 did not report whether any adjunc-
tive treatments were used.
Donor methods
Four studies used multiple donors (i.e. a pooled 
sample),14,53,54,64 two did not adequately describe 
whether single or multiple donors were used,46,63 
and the remaining 20 studies used single donors. 
Nineteen studies used non-related donors, two 
used related donors only,55,62 one used either,56 
and four did not specify.46,57,63,64
Screening protocol
Donor screening protocols overall were incomple-
tely and poorly described. Where screening was 
stated as occurring, the methods for screening 
were frequently not provided. However, the more 
recent studies tended to have better reporting of 
screening protocols and more comprehensive 
screening. Fourteen studies specifically screened 
for metabolic risk factors, but only seven specifi-
cally described screening for mental illnesses.
Study results
Efficacy
Results were categorized by disorder and are summar-
ized in Table 2. Of the 26 included studies, 10 reported 
significant results for their primary outcome mea-
sures, where these related to clinical efficacy. These 
10 studies related to functional gut disorders,14,40,61,64 
Hepatitis B,63 IBD,53,54,57 antibiotic-resistant 
organisms,46 and metabolic syndrome.52 The evalu-
ated conditions were highly heterogeneous, even 
within groups. Nonetheless, it was possible to perform 
meta-analyses for two groups of disorders: IBS, and 
active UC.
Inflammatory bowel disease
There were eight studies of IBD, six of which were 
of active UC, the remaining two being of Crohn’s 
Disease (CD),45 and maintenance of remission in 
UC.60 Sokol et al45 conducted a randomized, single- 
blind, controlled trial comparing colonoscopic 
FMT with placebo in 17 adults with CD. There 
was a significant decrease in CD symptoms in the 
FMT group compared with placebo (p = .03).45 
Sood et al60 conducted a double-blind, rando-
mized-controlled trial (RCT) of colonoscopic 
FMT compared with placebo as maintenance treat-
ment for inactive UC. The study did not find 
a significant difference in the primary outcome 
measure (steroid-free clinical remission) between 
groups (p = .111); however, significant between- 
group differences were reported in endoscopic 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(0.033), and change in inflammatory markers 
(p < .001) favoring FMT.60
Meta-analysis for ulcerative colitis subgroup
Six studies reported on active UC, which was suffi-
cient to perform a meta-analysis for clinical remis-
sion, clinical response, endoscopic remission, and 
endoscopic response. Outcome measures were het-
erogeneous, were collected at different time points 
(between 7 weeks and 90 days), and used differing 
definitions of clinical response/remission and 
endoscopic remission/response. Five of six used 
Mayo score, whilst one used Clinical Activity 
Index (CAI) score. Definitions and data for clinical 
remission and response are summarized in 
Supplementary Table 1, and endoscopic remission 
and response are summarized in Supplementary 
Table 2.
Meta-analysis confirmed that FMT was asso-
ciated with a significant improvement in clinical 
remission rates in UC compared to control condi-
tions (OR = 3.634, 95% CI = 1.940 to 6.808, n = 6 
studies, I2=0%, p < .001) (see Figure 2). FMT was 
also associated with a significant improvement in 
clinical response rates in UC compared to control 
(OR = 2.634, 95% CI = 1.441 to 4.815, n = 6 studies, 
I2=33%, p = .002) (see Figure 3), as well as for 
endoscopic remission rates (OR = 4.431, 95% 
CI = 1.901 to 10.324, n = 5 studies, I2=0%, p 
= .001) (see Figure 4). However, FMT showed no 
significant improvement in endoscopic response 
rates in UC compared to controls (OR = 1.065, 
Figure 2. Clinical remission results.
Figure 3. Clinical response results.
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95% CI = 0.432 to 2.625, n = 2 studies, I2=0%, p 
= .892) (see Supplementary Fig 1).
Functional gut disorders
In a trial of nasojejunally delivered FMT given daily 
for six days in adjunct to treatment as usual (TAU) 
for slow-transit constipation, Tian et al61 reported 
a clinical remission rate of 36.7% for the FMT 
group compared with 13.3% for the TAU control 
group (p = .04).
Five studies reported on IBS, which was suffi-
cient to perform a meta-analysis for clinical 
response and average change in IBS-SSS. Different 
studies used different definitions of clinical 
response: four used IBS-SSS, and one used GSRS- 
IBS, mostly at 3 months. Definitions and data for 
clinical response and change in IBS-SSS are sum-
marized in Supplementary Table 3.
Meta-analysis revealed no significant difference 
in IBS-SSS (Hedge’s g = 0.282, 95% CI = −1.373 to 
1.937, n = 3 studies, I2=97%, p = .739) or clinical 
response (OR = 1.699, 95% CI = 0.273 to 10.588, 
n = 5 studies, I2=92%, p = .739) following FMT 
compared to control (see Supplementary material; 
Figures 2 and 3)
Psychiatric outcomes
Only three studies assessed psychiatric outcomes 
and all three were conducted in IBS populations. 
Two of the studies used the Hospital Anxiety and 
Depression Scale (HADS) to measure depression 
and anxiety symptoms and neither reported 
a significant change in symptoms between groups 
post-intervention. The third study used the mental 
health subscale of the Fatigue Assessment Scale 
(FAS), and reported a significant difference 
between the means of the group who received 
30 g FMT (13.3, s.d. 3.1) compared with the placebo 
group (14.7, s.d. 3.4) at 1 month (p < .05), and the 
group who received 60 g FMT (13.1, s.d. 3.1), com-
pared with the placebo group (14.5, s.d. 2.7) at 
3 months (p < .05) in favor of FMT.
Hepatic disorders
Of the four studies in hepatic disorders, three had 
significant results for clinical efficacy favoring FMT 
over control, whilst the fourth did not report signifi-
cant outcomes. In a trial of nasoduodenally delivered 
FMT every 4 weeks (for 1–7 treatments) plus TAU for 
Hepatitis B, Ren et al63 reported that four of the five 
participants achieved clearance of HbeAg, whereas all 
13 of the TAU controls continued to have a positive 
HbeAg titer (p = .0002). Bajaj et al48 conducted an 
open-label RCT investigating FMT for recurrent 
hepatic encephalopathy using a retention enema 
compared with TAU and reported a significant 
improvement in two measures of cognitive out-
comes in favor of FMT (p < .01 for both). Similarly, 
in a single-blind RCT of encapsulated FMT com-
pared with placebo capsules, Bajaj et al49 found 
a significant improvement in cognitive outcomes 
for the FMT group but not the placebo group 
(p = .02). Philips et al62 conducted a retrospective 
cohort study comparing FMT with three control 
groups (steroids, nutritional support or pentoxi-
fylline) for the treatment of severe alcoholic hepa-
titis, but found no significant improvement in the 
primary outcome of 90-day survival (p = .179).
Figure 4. Endoscopic remission results.
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Metabolic syndrome or obesity without metabolic 
syndrome
Four studies evaluated FMT for the treatment of 
metabolic syndrome or obesity without metabolic 
syndrome, and only one of these had significant 
results for clinical efficacy regarding the primary 
outcome. The remaining three showed significant 
results for secondary outcome measures, all in favor 
of FMT. Vrieze et al52 conducted a double-blind 
pilot RCT of nasoduodenally delivered FMT com-
pared with autologous FMT for metabolic syn-
drome and reported a significant improvement in 
week 6 peripheral insulin sensitivity (p < .05) in 
favor of FMT, but not in hepatic insulin sensitivity 
(p = .08), diet composition, resting energy expen-
diture, or counter-regulatory hormones. In 
a double-blinded RCT examining nasoduodenally 
delivered FMT for metabolic syndrome, Kootte et -
al39 did not find significant differences in their 
primary outcome measure (change in intestinal 
microbiota in relation to insulin sensitivity at 
18 weeks), nor did they observe a significant change 
in BMI or SCFA levels at any study time point. In 
terms of secondary outcomes, change in fecal 
microbiota composition at 6 weeks associated 
with improved peripheral insulin sensitivity (from 
25.8 [19.3–34.7] to 28.8 [21.4–36.9] mmol kg/ 
1 min/1, p < .05) in the allogenic FMT group, 
whereas autologous FMT had no effect (from 22.5 
[16.9–30.2] to 20.8 [17.6–29.5] mmol kg/1 min/ 
1, p > .5).
Smits et al43 conducted a double-blind pilot RCT 
of nasoduodenally delivered FMT compared with 
autologous FMT for TMAO production in partici-
pants with metabolic syndrome and did not find 
a significant difference between groups. In 
a double-blind pilot RCT of encapsulated FMT 
compared with placebo capsules for obesity- 
related biomarkers in participants with obesity but 
without metabolic syndrome, Allegretti et al found 
a significant between-group difference in area 
under the curve at week 12 for leptin compared 
with baseline (p = .001), but no significant change 
for other biomarkers of obesity.50
Antibiotic-resistant organisms
Two studies evaluated FMT for the treatment of 
colonization of antibiotic-resistant organisms, one 
demonstrating significant clinical efficacy of FMT 
over control and the other without significant out-
comes. In a retrospective matched case-control 
study of nasogastric FMT compared with TAU for 
Carbapenemase-Producing Enterobacteriaceae 
(CPE), Saidani et al46 reported a significant delay 
in negativation of rectal swab cultures 2-weeks 
post-FMT compared with TAU (p < .001). 
Huttner et al59 conducted a multicentre, rando-
mized, open-label, superiority trial of nasogastric 
or encapsulated FMT (treatment was site depen-
dant), compared with TAU for CPE and Extended 
spectrum beta-lactamase (ESBL), but did not iden-
tify a significant between-group difference in the 
primary outcome measure for clinical efficacy 
(p-value not provided).
Other conditions
Two studies were not able to be grouped with the 
others. They evaluated FMT for the treatment of 
individuals with HIV and antibiotic-dependant 
pouchitis, respectively. Neither showed clinical 
efficacy.
Safety data
There were variable quality and completeness of 
reporting of safety data for both serious adverse 
events (SAEs) and mild to moderate AEs, across 
studies (see Table 3). Studies had a follow up period 
ranging from four weeks55 to 1 year .14 SAEs
Of the 26 included studies, 23 provided clear 
descriptions of SAEs. A total of 69 SAEs were 
reported from 12 studies; 26 occurred in partici-
pants allocated to receive FMT, and 43 in partici-
pants in the control groups (see Supplementary 
Table 4). Of the 26 SAEs that occurred in partici-
pants allocated to receive FMT, all but one was 
deemed unlikely to be related to the intervention. 
Table 3. Completeness of reporting of AE.
Completeness of reporting of AE
Number reported (total studies, 
n = 26)
Mild-moderate AE
Detailed reporting of AE 9 (34.6%)
Generic statement only or limited 
reporting of AE
9 (34.6%)
Not reported at all 8 (30.8%)
SAE
Clearly described 23 (88.5%)
Not reported at all or not clearly 
reported
3 (11.5%)
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Twenty of these SAEs occurred in participants who 
received FMT via colonoscopy or enema, and six in 
those receiving FMT endoscopically or via capsules. 
When broken down by specific disorder, 17 of these 
SAEs occurred in participants with inflammatory 
bowel disease, three in participants with hepatic 
encephalopathy, five in participants with antibiotic 
resistant organisms and one in a participant 
with IBS.
Mild to moderate AEs
Due to the inconsistent quality and completeness of 
reporting of mild to moderate AE, it was only 
possible to pool/summarize data for a small num-
ber of included studies (see Supplementary 
Table 5). These studies were related to IBS, 
(n = 4), UC (n = 2), slow transit constipation 
(n = 1), hepatic encephalopathy (n = 1), and meta-
bolic syndrome (n = 1). As such a cross-indication 
assessment of adverse events was not possible as the 
data were insufficiently reported across disorders.
Similar rates of mild to moderate AEs were 
observed in participants allocated to FMT com-
pared to the control groups (see Supplementary 
Table 5). However, the following AEs were more 
common in participants receiving allogenic FMT 
compared with those allocated to control groups: 
nausea (reported in 80% of FMT recipients com-
pared with 72% in control groups), constipation 
(reported in 17.4% of FMT recipients compared 
with 2.4% in control groups), diarrhea (reported 
in 16.8% of FMT recipients compared with 6.7% 
in control groups), transient, or low-grade fever 
(reported in 8.4% of FMT recipients compared 
with 3.0% in control groups) and vomiting 
(reported in 5.9% of FMT recipients compared 
with 2.9% in control groups).
Incomplete reporting precluded comparison of 
AE rates between different routes of FMT; however, 
encapsulated FMT appears to have been the best- 
tolerated route.
Successful microbial “engraftment”
Microbiome analysis pre- and post-FMT was per-
formed in 23 of the 26 included studies. All micro-
biome analyses used 16s RNA sequencing. The data 
relating to “engraftment” are summarized in Table 4. 
All 23 of 23 studies which measured microbiome 
analysis reported change in microbiome following 
FMT. Fourteen of the 23 studies reported whether 
the change in microbiota was toward the donor and, 
of these, 11 confirmed that the recipient microbiome 
did move toward the donor microbiome. The 
remaining three studies did not report significant 
results.
Reporting on the extent or significance of micro-
biota changes was inconsistent across studies and 
the complexity of microbiome data analysis has 
meant it was not possible to answer the question 
of the extent to which the recipient microbiome 
changed toward the donor, as no clear quantifica-
tion was provided by the included studies. As such, 
these data are not reported in Table 4.
Regarding longevity of the observed changes in 
recipient microbiota, it was not possible to answer 
this question in this review, as included studies 
either did not follow-up recipients for long enough, 
or did not measure microbiota changes frequently 
enough to be able to state the duration for which 
any changes were observed. However, with these 
limitations in mind, it appears that the demon-
strated microbiome changes were transient and 
appeared to last between 2 weeks to 1 year follow-
ing the intervention.
Correlation of “engraftment” with clinical findings
Fourteen of 23 studies reported on associations 
between “engraftment” and clinical outcomes, and 
of these, 12 studies had statistically significant results 
with 10 reporting a significant association between 
successful engraftment and clinical efficacy and two 
reporting no association between efficacy and engraft-
ment. These data are summarized in Table 4.
Risk of bias assessment
According to the Cochrane Risk of Bias tool36 (see 
Supplementary Table 6), nine studies were evaluated 
as “low risk,”14,40–42,49,53,54,58,60,64 six as “some 
concerns,”39,42,43,45,50,52,57 and five as “high 
risk.”48,57–59,61 Studies rated “high risk” were: Tian 
et al,61 due to incomplete reporting across most 
domains and inadequate randomization processes; 
Moayyedi et al57 due to likely inadequacy of blinding 
of participants as water enemas were used as placebo, 
which would likely be easily differentiated from true 
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the studies were open label, with an absence of blind-
ing; and Herfarth et al,51 due to an absence of 
a statistical pre-analysis plan, and the fact that the 
trial was ceased after only six participants were 
randomized.
Discussion
Statement of principal findings
This review identified FMT trials for conditions other 
than CDI, with promising, albeit mixed, outcomes 
regarding efficacy and safety. Meta-analysis of UC 
studies found FMT to be superior to control condi-
tions for active disease in terms of endoscopic remis-
sion, clinical remission, and clinical response. In 
contrast, meta-analysis of the five IBS studies did 
not yield significant results regarding symptoms or 
clinical response. Regarding clinical efficacy in other 
applications of FMT, studies were too heterogeneous 
to perform meta-analyses, but four yielded evidence 
of clinical efficacy in slow-transit constipation, 
Hepatitis B, colonization of CPE, and insulin sensitiv-
ity in metabolic syndrome. The impact of FMT on 
psychiatric outcomes was assessed in three studies of 
IBS patients, with one of these finding significant 
improvements.
This review also found that FMT was safe and well 
tolerated. Similar rates of mild to moderate AEs were 
observed in participants who received FMT compared 
to those allocated to control groups, while SAEs were 
more commonly reported in participants allocated to 
control/placebo groups.
Not all studies assessed or reported whether FMT 
results in successful engraftment of the donor micro-
biome into the recipient, but a majority of those that 
did report it confirmed a move toward the donor 
microbiome following FMT and that these changes 
persisted for up to 1 year. Furthermore, four of the 
five studies that reported on association between 
microbiome changes and clinical efficacy, four of 
five confirmed such an association. This suggests 
that FMT alters the recipient microbiome, and that 
it is possible that this change is a contributing factor to 
clinical efficacy.
Strengths and weaknesses of the review
This review is the first systematic review to evaluate 
both safety and efficacy of FMT for all disorders 
other than CDI. This review aimed to recruit higher 
quality studies by excluding uncontrolled studies, 
which represent a majority of studies in this field. 
Whilst other reviews have been conducted with 
respect to safety of FMT for indications other 
than CDI, these reviews are either not recent,65 or 
were restricted to a single indication such as 
IBS29–31 and IBD.32–34 With respect to efficacy, 
whilst other reviews have been published for single 
indications, such as IBS29–31 and IBD,32–34 there 
have been no holistic reviews looking at all indica-
tions other than CDI. As far as the authors of this 
review are aware, this review also represents the 
most up to date systematic review and meta- 
analysis of the safety and efficacy of FMT for IBS.
However, the 26 studies included were hetero-
geneous and of mixed quality, with several using 
open-label designs and small samples. 
Encouragingly, more recently published studies 
appear to be of higher quality, using more robust 
study designs (such as double-blinded RCTs), and 
with clearer and more complete descriptions of 
study methodology.
It was possible to conduct meta-analyses for both 
IBS and active UC. However, due to the lack of 
consensus regarding outcome measures and small 
number of included studies, the results of these 
meta-analyses should be considered preliminary at 
this stage. Further, due to the low numbers, tests for 
publication bias (e.g. eggers regression and funnel 
plots) were unable to be carried out.
We were unable to undertake a quantitative ana-
lysis on the level of engraftment, given the gaps in 
data in the included studies. Future studies should 
evaluate microbial engraftment as a result of FMT, 
allowing for a systematic assessment.
This paper evaluated safety data across a range of 
indications, finding broadly that FMT is well toler-
ated and safe. However, due to the poor quality and 
incompleteness of reporting in several papers, 
a cross-indication analysis of safety data was not 
possible. We recommend future FMT studies 
report more clearly on mild to moderate and SAE.
With respect to SAE, these were observed more 
frequently in control group participants than those 
allocated to receive FMT, and of the SAE observed 
in FMT recipients, most considered to be unrelated 
to FMT. In understanding this finding, it should be 
noted that most SAE were likely due to the 
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underlying disease process rather than the FMT 
procedure, a majority of reported SAE were flares 
of the disease in inflammatory bowel disease parti-
cipants. Thus, FMT may have prevented disease 
flares.
Implications for clinicians and policymakers
With respect to active UC, our meta-analysis 
revealed that FMT appears to be clinically effica-
cious compared to control conditions. Four of the 
six included studies used a gold-standard double- 
blind placebo-controlled RCT design, and all six 
included studies favored FMT over control condi-
tions regarding clinical efficacy, notwithstanding 
limitations described above. Thus, the quality and 
consistency of outcomes appear to favor FMT in 
the treatment of active UC, making this is 
a promising area for research attention.
Evidence supporting the application of FMT in 
the treatment of IBS is more equivocal. Five studies 
included in this review showed mixed outcomes, 
with three reporting that FMT was favorable, and 
two finding that control conditions were more 
effective than FMT. Possible reasons for these 
mixed findings are discussed in depth in other 
review papers,29–31 which note, inter alia, that 
route of delivery, choice of placebo (i.e. inert vs 
autologous FMT), and patient group may have 
contributed.29–31 Suffice to say, there is no strong 
evidence at this stage that FMT is efficacious for the 
treatment of functional gut disorders.
This review also identified two additional studies 
relating to inflammatory bowel disease yielding 
significant outcomes regarding clinical efficacy, 
and four studies that evaluated FMT for metabolic 
syndrome or obesity that focused on biological out-
comes rather than clinical efficacy. As such, these 
are identified as conditions of interest for further 
research only.
Regarding safety, FMT appears generally to be 
a safe and well-tolerated treatment, with orally admi-
nistered FMT appearing to be the best-tolerated route. 
However, it is also important to note that on 13th 
June, 2019 the American-based Food and Drug 
Administration (FDA) released a statement warning 
of the risks of FMT. They reported two cases (both 
immunocompromised patients) in whom antibiotic- 
resistant organisms, (specifically, Extended Spectrum 
Beta Lactamase-producing Escherichia coli (E.coli)) 
were transferred via FMT, resulting in one death. In 
these cases, donor feces were not screened for anti-
biotic-resistant organisms.66 A further warning was 
issued on 12th March 2020 advising of six cases of 
additional transmission of antibiotic-resistant organ-
isms via FMT provided by a US-based stool bank 
(enteropathogenic Escherichia coli in two cases and 
Shigatoxin-producing Escherichia coli in four cases) 
and two deaths that occurred in recipients of FMT, 
but in which FMT may not have been the cause of 
death.67 It is now standard across widely accepted 
protocols in the United Kingdom, United States, and 
Australasia to screen thoroughly for antibiotic- 
resistant organisms. These recent serious incidents 
highlight the importance of adhering to rigorous 
screening protocols, such as the Openbiome 
Protocol in the US,68 the British Guidelines for 
donor screening,69 or the Australasian guidelines.70
Unanswered questions, challenges for the field of 
FMT research, and future directions
Of all the uses of FMT for conditions other than 
CDI, the most promising at this stage is for active 
flares of UC. Further large scale, high-quality stu-
dies, utilizing consistent data points to measure 
primary outcomes, are urgently called for. Other 
indications with some promise include metabolic 
syndrome/obesity, antibiotic-resistant organisms, 
and certain hepatic disorders. Whilst published 
outside of the time range of the search performed 
for this review, a recent Phase I study investigating 
FMT for Alcohol Use Disorder showed safety and 
efficacy.71 Thus, we watch with interest the growing 
field of FMT for hepatic disorders.
However, on the whole, studies in these emer-
ging areas are heterogeneous and generally of poor 
quality, with most using open-label designs and 
only one study using clinical efficacy as a primary 
outcome measure. Again, further high-quality 
research, using larger sample sizes and double- 
blinded, placebo-controlled designs, and that use 
clinical efficacy endpoints as a primary outcome, 
are needed for these emerging indications. 
Furthermore, no studies evaluated the use of FMT 
for psychiatric conditions, an area of great impor-
tance given growing interest and data supporting 
the relationship between mental health and the gut 
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microbiome (“the microbiota-gut-brain axis”).7,72 
Much also remains unknown about the ideal meth-
odological design for studies of FMT for conditions 
other than Clostridium difficile infection. For one, 
an important question remains around choice of 
placebo. Nine studies selected an inert placebo, 
such as water mixed with glycerol and food dye, 
whilst eight opted for autologous FMT as a placebo. 
There is some evidence to suggest that even auto-
logous FMT may have an impact on gut 
microbiota,58 which may confound results. This 
needs to be further explored but presents an argu-
ment against using autologous FMT as a placebo in 
future studies aimed at determining efficacy of 
FMT compared with an inactive control. Follow- 
up periods to assess long-term safety, engraftment, 
and metagenomics are also an important consid-
eration for study design. The authors of this review 
suggest a follow up period of at least 6 months to 
adequately monitor for safety and long-term AE.
Conclusions
This systematic review and meta-analysis provide 
preliminary data that FMT may be safe and effec-
tive for several conditions other than CDI. 
Preliminary meta-analyses suggest efficacy for out-
comes related to active ulcerative colitis but not 
IBS. Hepatic disorders, metabolic syndrome/obe-
sity, and antibiotic-resistant organisms were also 
identified as emerging areas of interest for FMT 
research. Regarding safety, there was little differ-
ence in SAEs between participants allocated to 
receive FMT and those allocated to control groups. 
With respect to mild to moderate adverse events, 
similar rates were also observed in treatment and 
control groups. These encouraging pilot outcomes 
provide preliminary support for further high- 
quality research in these areas.
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